7Baggers
 If You Invested $1,000 in 89Bio, Inc. (ETNB)  Stock Titan Mon, 06 Jul 2026 02:43:40 GMT
 89bio inc (etnb) institutional confidence  TradingKey Wed, 17 Jun 2026 21:55:44 GMT
 89bio inc (etnb) valuation: pe, pb & fair value analysis  TradingKey Wed, 17 Jun 2026 21:47:03 GMT
 why is 89bio, inc. (etnb) stock down today?  Meyka Tue, 02 Jun 2026 02:18:23 GMT
 89bio stock (us28252c1099): delisting amid liquidation process  AD HOC NEWS Thu, 14 May 2026 07:00:00 GMT
 roche to acquire 89bio in deal worth up to $3.5 billion  MSN Mon, 27 Apr 2026 02:58:38 GMT
 roche to acquire 89bio in deal worth up to $3.5 billion  MSN Fri, 17 Apr 2026 10:04:30 GMT
 roche to acquire 89bio in deal worth up to $3.5 billion  MSN Thu, 16 Apr 2026 11:46:08 GMT
 why did 89bio stock nearly double in value today?  MSN Thu, 26 Mar 2026 21:53:49 GMT
 Brugnoli develops fabric with 89% bio-based content  World Bio Market Insights Fri, 20 Mar 2026 07:00:00 GMT
 roche deal to buy 89bio boosts mash space  MSN Fri, 13 Mar 2026 11:43:56 GMT
 etnb - 89bio, inc. latest stock news & market updates  Stock Titan Sat, 07 Mar 2026 16:38:47 GMT
 89bio stock (etnb): a deep dive into the roche acquisition  Bitget Mon, 02 Mar 2026 03:08:43 GMT
 etnb - 89bio, inc. latest stock news & market updates  Stock Titan Thu, 26 Feb 2026 21:32:18 GMT
 life sciences group of the year: gibson dunn  Law360 Tue, 24 Feb 2026 08:00:00 GMT
 combination therapy for ldl cholesterol lowering  Medscape Mon, 26 Jan 2026 08:00:00 GMT
 precision trading with 89bio inc. (etnb) risk zones  Stock Traders Daily Thu, 22 Jan 2026 10:04:02 GMT
 should you buy 89bio (etnb) after golden cross?  MSN Mon, 05 Jan 2026 16:49:30 GMT
 why 89bio stock lagged the market today  MSN Sat, 20 Dec 2025 00:34:29 GMT
 89bio Inc (NASDAQ: ETNB) Stock Price, News & Analysis  Kalkine Thu, 04 Dec 2025 08:00:00 GMT
 [effect] 89bio, inc. sec filing  Stock Titan Wed, 19 Nov 2025 08:00:00 GMT

89bio, Inc
(NASDAQ:ETNB) 

ETNB stock logo

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is BIO89-100, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalc...

Founded: 2018
IPO Price: $16 (Nov 11, 2019)
Full Time Employees: 25
CEO: Rohan Palekar  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends